Maetzold Derek J's Form 4 filing
Castle Biosciences IncCSTL · filed Oct 7, 2026
- Accession no.
- 0001628280-26-065327
- Filed
- Oct 7, 2026, 4:10 PM ET
- Trade date
- Oct 5, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 4 non-derivative transactions and 1 derivative transaction. Open-market sales total $515.6K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Maetzold Derek JCIK 0001239501 | Director, Officer (Pres. & Chief Exec. Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 5, 2026 | Common Stock | MOption exerciseAcquired | +8,165 | $2.39 | +$19,514.35 | 29,644 | Direct | |
| Oct 5, 2026 | Common Stock | SSaleDisposed | −8,580 | $35.57F2 | −$305,156.28 | 21,064 | Direct | |
| Oct 5, 2026 | Common Stock | SSaleDisposed | −3,198 | $35.57F2 | −$113,740.07 | 8,038 | Indirect | |
| Oct 5, 2026 | Common Stock | SSaleDisposed | −2,718 | $35.57F2 | −$96,668.39 | 6,832 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 5, 2026 | Common Stock | MOption exerciseDisposed | −8,165 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
This transaction was executed in multiple trades at prices ranging from $35.310 to $35.965, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 3 transactions in Table I.